EVOQUANT
@evoquant.bsky.social
Evoquant uses AI and bioinformatics to harness microbes, exploring billions of years of evolution to uncover new drug compounds and accelerate treatments for cancer, infectious diseases, and rare conditions.
https://evoquantbio.com/
https://evoquantbio.com/
Pinned
I am excited to announce that registration is now open for the 10th Annual Stanford Drug Discovery Symposium (SDDS 2026), taking place on April 27–28, 2026, at the Frances C. Arrillaga Alumni Center… ...
I am excited to announce that registration is now open for the 10th Annual Stanford Drug Discovery Symposium (SDDS 2026), taking place on April 27–28, 2026, at the Frances C. Arrillaga Alumni Center a...
www.linkedin.com
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
First time attending and looking forward to it.
Reposted by EVOQUANT
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
First time attending and looking forward to it.
I am excited to announce that registration is now open for the 10th Annual Stanford Drug Discovery Symposium (SDDS 2026), taking place on April 27–28, 2026, at the Frances C. Arrillaga Alumni Center… ...
I am excited to announce that registration is now open for the 10th Annual Stanford Drug Discovery Symposium (SDDS 2026), taking place on April 27–28, 2026, at the Frances C. Arrillaga Alumni Center a...
www.linkedin.com
January 20, 2026 at 11:40 PM
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
First time attending and looking forward to it.
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
First time attending and looking forward to it.
I am excited to announce that registration is now open for the 10th Annual Stanford Drug Discovery Symposium (SDDS 2026), taking place on April 27–28, 2026, at the Frances C. Arrillaga Alumni Center… ...
I am excited to announce that registration is now open for the 10th Annual Stanford Drug Discovery Symposium (SDDS 2026), taking place on April 27–28, 2026, at the Frances C. Arrillaga Alumni Center a...
www.linkedin.com
January 20, 2026 at 11:40 PM
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
First time attending and looking forward to it.
Reposted by EVOQUANT
Evoquant received SBIR funding from the NIH in 2025 to develop new/better methods for finding anti-cancer and antibacterial small molecules produced by bacteria
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
The Federal Government’s Research Innovation Lifeline Has Gone Dark
Congressional inaction has led to the expiration of the federal government’s SBIR/STTR program, cutting off a biotechnology lifeline.
www.the-scientist.com
January 18, 2026 at 3:04 PM
Evoquant received SBIR funding from the NIH in 2025 to develop new/better methods for finding anti-cancer and antibacterial small molecules produced by bacteria
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
Evoquant received SBIR funding from the NIH in 2025 to develop new/better methods for finding anti-cancer and antibacterial small molecules produced by bacteria
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
The Federal Government’s Research Innovation Lifeline Has Gone Dark
Congressional inaction has led to the expiration of the federal government’s SBIR/STTR program, cutting off a biotechnology lifeline.
www.the-scientist.com
January 18, 2026 at 3:04 PM
Evoquant received SBIR funding from the NIH in 2025 to develop new/better methods for finding anti-cancer and antibacterial small molecules produced by bacteria
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
Reposted by EVOQUANT
I have been struggling with transfers in AWS between EC2 and S3 being way slower than the advertised EC2 bandwidth
Last week I learned about:
aws configure set s3.preferred_transfer_client crt
and now transfers are super duper fast.
The more you know
Last week I learned about:
aws configure set s3.preferred_transfer_client crt
and now transfers are super duper fast.
The more you know
November 17, 2025 at 3:47 PM
I have been struggling with transfers in AWS between EC2 and S3 being way slower than the advertised EC2 bandwidth
Last week I learned about:
aws configure set s3.preferred_transfer_client crt
and now transfers are super duper fast.
The more you know
Last week I learned about:
aws configure set s3.preferred_transfer_client crt
and now transfers are super duper fast.
The more you know
🚀 Evoquant has been awarded a $300k Small Business Grant from the National Institutes of Health for our project:
"Leveraging Large-Scale Bioinformatics & AI for Natural Product Drug Discovery and Target Selection"
Hitting the ground running 🏃and excited for the year to come!
"Leveraging Large-Scale Bioinformatics & AI for Natural Product Drug Discovery and Target Selection"
Hitting the ground running 🏃and excited for the year to come!
September 15, 2025 at 11:51 PM
🚀 Evoquant has been awarded a $300k Small Business Grant from the National Institutes of Health for our project:
"Leveraging Large-Scale Bioinformatics & AI for Natural Product Drug Discovery and Target Selection"
Hitting the ground running 🏃and excited for the year to come!
"Leveraging Large-Scale Bioinformatics & AI for Natural Product Drug Discovery and Target Selection"
Hitting the ground running 🏃and excited for the year to come!